# Premarket Requirements - Complete 510(k) Cybersecurity Checklist

**FDA Guidance:** Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (September 2023)

**Legal Foundation:** Section 524B of the FD&C Act (effective March 29, 2023)

---

## Section 524B Core Requirements

All "cyber devices" (devices with software, connectivity, or programmability vulnerable to cybersecurity threats) MUST include:

1. **Postmarket vulnerability monitoring and coordinated vulnerability disclosure (CVD) plan**
2. **Processes ensuring reasonable cybersecurity assurance including software updates/patches capability**
3. **Software Bill of Materials (SBOM)**

**Applicable submissions:** 510(k), PMA, PDP, De Novo, HDE

---

## SBOM Requirements

### Content Requirements (No Format Mandate)

FDA does **NOT** mandate SPDX 2.3+ or CycloneDX 1.4+. However, SBOM must include:

1. **Software component identification**
   - Commercial software components (COTS, SOUP, OTS)
   - Open-source components
   - Custom/proprietary software modules
   - Firmware components

2. **Version information**
   - Specific version numbers for all components
   - Build identifiers where applicable

3. **Supplier/source information**
   - Component manufacturer/publisher
   - Origin (e.g., npm registry, GitHub, commercial vendor)

4. **Level of support**
   - Active support status
   - End-of-life dates
   - Maintenance commitments

5. **Known vulnerabilities**
   - CVE identifiers for known vulnerabilities
   - Vulnerability severity scores (CVSS)
   - Mitigation status

6. **Component dependencies**
   - Transitive dependencies
   - Dependency tree depth

**Format flexibility:** Any machine-readable or human-readable format acceptable. SPDX and CycloneDX are industry best practices but voluntary.

---

## Cybersecurity Plan Components

### 1. Postmarket Vulnerability Monitoring & CVD

#### Monitoring Plan Elements
- Continuous monitoring methods (threat intelligence feeds, vulnerability scanners)
- Triage and risk assessment procedures
- Severity scoring methodology (CVSS + patient harm)
- Timeline for assessment based on severity
- Escalation procedures for critical findings

#### CVD Policy Documentation
- External researcher reporting channels (email, web form, security.txt)
- Acknowledgment timelines (48-72 hours)
- Non-retaliation and safe harbor provisions
- Bug bounty program (if applicable)
- Internal CVD workflow (Intake → Triage → Remediation → Communication)

#### Communication Plans
- Stakeholder notification procedures (healthcare providers, patients, distributors)
- Notification methods (Field Safety Notices, security bulletins, customer portals)
- Risk-based timelines:
  - Critical vulnerabilities: Immediate notification (24-48 hours)
  - High severity: 1-2 weeks
  - Medium/Low: 30-60 days

### 2. Software Updates, Patches, and Maintenance

#### Update Capability
- Delivery mechanisms (OTA updates, USB, service tool, cloud-based)
- Secure update technical controls:
  - Cryptographic signing (code signing certificates)
  - Authenticity verification (signature validation)
  - Integrity checks (hash verification, checksums)
  - Rollback protection mechanisms
  - Access control for update initiation
  - Update channel encryption (TLS/SSL)

#### Deployment Strategy
- Phased rollout capabilities
- Pilot/canary deployment support
- Emergency patch deployment procedures
- Rollback procedures for failed updates
- Pre-deployment testing requirements

#### Lifecycle Management
- Support lifecycle definition (5-10 years)
- End-of-support (EOS) communication plan
- Legacy device migration strategies
- Update frequency commitments (monthly, quarterly)

### 3. Design Considerations for Cybersecurity

#### Secure-by-Design Principles
- Defense-in-depth layering
- Least privilege access controls
- Network segmentation and isolation
- Trust boundary definitions
- Zero-trust architecture principles

#### Authentication and Access Control
- Multi-factor authentication (MFA) implementation
- Role-based access control (RBAC)
- Password/credential management (complexity, rotation)
- Account lockout and monitoring
- Privileged access management

#### Data Protection
- Encryption at rest (AES-256, etc.)
- Encryption in transit (TLS 1.3+)
- Key management and storage
- Data integrity protections
- Secure data deletion/sanitization

---

## Security Testing Standards

### FDA Expectations (Methodology-Agnostic)

FDA requires **reasonable assurance of cybersecurity** but does NOT mandate specific testing tools.

### 1. Threat Modeling

**Accepted methodologies:**
- STRIDE (Spoofing, Tampering, Repudiation, Information Disclosure, Denial of Service, Elevation of Privilege)
- Attack Trees / Misuse Cases
- Kill Chain / Attack Lifecycle Models
- PASTA (Process for Attack Simulation and Threat Analysis)

**Key requirement:** Comprehensive, documented, traceable to controls and testing

**Deliverables:**
- Threat model report
- Architecture diagrams
- Traceability matrix (Threats → Security controls → Verification testing)
- Risk assessment tables (pre/post-mitigation)

### 2. Vulnerability Assessment

- **Static Analysis**: Source code SAST, manual code review for critical components
- **Software Composition Analysis (SCA)**: SBOM-based CVE matching, transitive dependency analysis
- **Network vulnerability scanning**: Authenticated/unauthenticated scans, SSL/TLS testing
- **Web application scanning**: OWASP Top 10, authentication testing

### 3. Penetration Testing

**Scope:**
- Black-box, gray-box, or white-box testing
- Authentication and authorization bypass
- Network protocol exploitation
- API security testing
- Cryptographic implementation weaknesses
- Privilege escalation
- Data exfiltration and tampering

**Deliverables:**
- Penetration test report with findings
- Proof-of-concept exploits (where applicable)
- Risk ratings for each finding
- Retest results after fixes

### 4. Secure Development Lifecycle (SDL) Integration

- **Design Phase**: Security requirements, threat modeling, security design review
- **Implementation Phase**: Secure coding standards, peer code review, static analysis (CI)
- **Testing Phase**: Security test cases, vulnerability scanning, penetration testing, fuzz testing
- **Release Phase**: Final security assessment, SBOM generation, security documentation

---

## eSTAR Submission Template

FDA expanded eSTAR template from 2 attachments to **12 attachments and 9 questions** for cybersecurity:

1. Cybersecurity plan (CVD + monitoring + updates)
2. SBOM (any format with required content)
3. Threat model report
4. Architecture diagrams
5. Data flow diagrams
6. Security testing report (vulnerability assessment)
7. Penetration testing report
8. Traceability matrix (Threats → Controls → Tests)
9. Residual risk justification
10. Secure development lifecycle documentation
11. Security labeling and user guidance
12. Quality system integration documentation (21 CFR 820.30 linkage)

---

## Common Causes of RTA (Refuse to Accept)

**15% of submissions receive RTA letters for inadequate cybersecurity documentation.**

### Documentation Failures
- **Incomplete SBOMs**: Missing versions, dependencies, known vulnerabilities
- **Fragmented documentation**: Cybersecurity docs not integrated with design controls
- **Missing traceability**: Threats not linked to controls and tests
- **Inadequate threat modeling**: 700% increase in deficiency letters since PATCH Act

### Technical Mistakes
- **Late-stage security additions**: Bolt-on security after design freeze causes redesign
- **Disconnects between risk assessments and test evidence**
- **Insufficient testing scope**: Missing penetration testing or vulnerability scanning

### Process Issues
- **Quality system disconnect**: Cybersecurity not integrated with 21 CFR 820.30 design controls
- **Missing CVD policy**: No documented external researcher reporting channels
- **Lack of update capability**: No demonstrated patch delivery mechanism

---

## Quality System Integration

**Critical:** Cybersecurity is **NOT a separate regulatory track**—it must integrate with:

- **21 CFR 820.30 (Design Controls)**: Security requirements, verification, validation
- **ISO 14971 (Risk Management)**: Cybersecurity risk assessment and mitigation
- **Postmarket Surveillance**: Vulnerability monitoring, complaint handling
- **MDR (Medical Device Reporting)**: Cybersecurity incident reporting

**Traceability required:** Threats → Controls → Tests → Risk management → Design controls

---

## Implementation Timeline

- **March 29, 2023**: Section 524B effective date
- **September 27, 2023**: FDA final guidance published
- **October 2023**: PATCH Act takes effect (700% increase in deficiency letters)
- **February 2, 2026**: ISO 13485:2016 compliance deadline
- **Ongoing**: Submissions not meeting requirements subject to RTA

---

## Key Regulatory References

- FDA Guidance: Cybersecurity in Medical Devices (September 2023)
  https://www.fda.gov/media/119933/download
- Section 524B of the FD&C Act
- 21 CFR 820.30 (Design Controls)
- ISO 14971:2007/(R)2010 (Medical Device Risk Management)
